TY  - JOUR
A1  - Lassonczyk, Beate
A1  - Alaily, F.
A1  - Huth, A.
A1  - Gensior, A.
T1  - Genesis of soils in the arid part of northeast Somalia / F. Alaily, B. Lassonczyk, A.Huth and A. Gensior
JF  - Berliner geowissenschaftliche Abhandlungen / Reihe A, Geologie und Paläontologie / hrsg. von d. Geowissenschaftlichen Instituten der Freien u. d. Technischen Universität Berlin. 120 A (1990)
Y1  - 1990
SN  - 0172-8784
SP  - 695
EP  - 711
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Snaith, Mike
A1  - Wolf, C. Roland
A1  - Seibler, Jost
T1  - Generation and utility of genetically humanized mouse models
JF  - Drug Discovery Today
Y1  - 2013
U6  - http://dx.doi.org/10.1016/j.drudis.2013.07.007
SN  - 1359-6446
VL  - Vol 18
IS  - 23-24
SP  - 1200
EP  - 1211
PB  - Elsevier
CY  - Amsterdam
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Kapelyukh, Yury
A1  - Rode, Anja
A1  - Buechel, Sandra
A1  - Wolf, C. Roland
T1  - Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines
JF  - Molecular Pharmacology
N2  - Compared with rodents and many other animal species, the human cytochrome P450 (P450) Cyp2c gene cluster varies significantly in the multiplicity of functional genes and in the substrate specificity of its enzymes. As a consequence, the use of wild-type animal models to predict the role of human CYP2C enzymes in drug metabolism and drug-drug interactions is limited. Within the human CYP2C cluster CYP2C9 is of particular importance, because it is one of the most abundant P450 enzymes in human liver, and it is involved in the metabolism of a wide variety of important drugs and environmental chemicals. To investigate the in vivo functions of cytochrome P450 Cyp2c genes and to establish a model for studying the functions of CYP2C9 in vivo, we have generated a mouse model with a deletion of the murine Cyp2c gene cluster and a corresponding humanized model expressing CYP2C9 specifically in the liver. Despite the high number of functional genes in the mouse Cyp2c cluster and the reported roles of some of these proteins in different biological processes, mice deleted for Cyp2c genes were viable and fertile but showed certain phenotypic alterations in the liver. The expression of CYP2C9 in the liver also resulted in viable animals active in the metabolism and disposition of a number of CYP2C9 substrates. These mouse lines provide a powerful tool for studying the role of Cyp2c genes and of CYP2C9 in particular in drug disposition and as a factor in drug-drug interaction.
Y1  - 2012
U6  - http://dx.doi.org/10.1124/mol.112.080036
SN  - 1521-0111
VL  - 82
IS  - 6
SP  - 1022
EP  - 1029
PB  - ASPET
CY  - Bethesda, Md.
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Balimane, Praveen
A1  - Hayward, Michael D.
A1  - Buechel, Sandra
A1  - Kauselmann, Gunther
A1  - Wolf, C. Roland
T1  - Generation and Characterization of a Novel Multidrug Resistance Protein 2 Humanized Mouse Line
JF  - Drug Metabolism and Disposition
N2  - The multidrug resistance protein (MRP) 2 is predominantly expressed in liver, intestine, and kidney, where it plays an important role in the excretion of a range of drugs and their metabolites or endogenous compounds into bile, feces, and urine. Mrp knockout [Mrp2(−/−)] mice have been used recently to study the role of MRP2 in drug disposition. Here, we describe the first generation and initial characterization of a mouse line humanized for MRP2 (huMRP2), which is nulled for the mouse Mrp2 gene and expresses the human transporter in the organs and cell types where MRP2 is normally expressed. Analysis of the mRNA expression for selected cytochrome P450 and transporter genes revealed no major changes in huMRP2 mice compared with wild-type controls. We show that human MRP2 is able to compensate functionally for the loss of the mouse transporter as demonstrated by comparable bilirubin levels in the humanized mice and wild-type controls, in contrast to the hyperbilirubinemia phenotype that is observed in MRP2(−/−) mice. The huMRP2 mouse provides a model to study the role of the human transporter in drug disposition and in assessing the in vivo consequences of inhibiting this transporter by compounds interacting with human MRP2.
Y1  - 2012
U6  - http://dx.doi.org/10.1124/dmd.112.047605
SN  - 1521-0111
VL  - 40
IS  - 11
SP  - 2212
EP  - 2218
PB  - ASPET
CY  - Bethesda, Md.
ER  - 
TY  - JOUR
A1  - Dallas, Shannon
A1  - Salphati, Laurent
A1  - Gomez-Zepeda, David
A1  - Wanek, Thomas
A1  - Chen, Liangfu
A1  - Chu, Xiaoyan
A1  - Kunta, Jeevan
A1  - Mezler, Mario
A1  - Menet, Marie-Claude
A1  - Chasseigneaux, Stephanie
A1  - Declèves, Xavier
A1  - Langer, Oliver
A1  - Pierre, Esaie
A1  - DiLoreto, Karen
A1  - Hoft, Carolin
A1  - Laplanche, Loic
A1  - Pang, Jodie
A1  - Pereira, Tony
A1  - Andonian, Clara
A1  - Simic, Damir
A1  - Rode, Anja
A1  - Yabut, Jocelyn
A1  - Zhang, Xiaolin
A1  - Scheer, Nico
T1  - Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model
JF  - Molecular Pharmacology
N2  - Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp−/−) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murine Bcrp promoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP.
Y1  - 2016
U6  - http://dx.doi.org/10.1124/mol.115.102079
SN  - 1521-0111
VL  - 89
IS  - 5
SP  - 492
EP  - 504
PB  - ASPET
CY  - Bethesda, Md.
ER  - 
TY  - JOUR
A1  - Scherer, Ulrich W.
A1  - Hör, G.
A1  - Kranert, W. T.
A1  - Maul, F. D.
T1  - Gated Metabolic Positron Emission Tomography (GAPET) of Myocardium: 18F-FDG/PET to optimize Recognition of Myocardial Hibernation / G. Hör, W.T. Kranert, F.D. Maul, O. Schröder,  A. Karimian-Tatriz, O. Geb, R.P. Baum, U.W.  Scherer
JF  - Nuclear Medicine Communications. 19 (1998)
Y1  - 1998
SN  - 0143-3636
SP  - 535
EP  - 545
ER  - 
TY  - JOUR
A1  - Scherer, Ulrich W.
A1  - Türler, A.
A1  - Gäggeler, H. W.
A1  - Gregorich, K. E.
T1  - Gas phase chromatography of halides of elements 104 and 105 / A. Türler, H. W. Gäggeler, K. E. Gregorich, H. Barth, W. Brüchle, K. R. Czerwinski, M. K. Gober, N. J. Hannink, R. A. Henderson, D. C. Hoffman, D. T. Jost, C. D. Kacher, B. Kadkhodayan, J. Kova
JF  - Journal of Radioanalytical and Nuclear Chemistry. 160 (1992), H. 2
Y1  - 1992
SN  - 0236-5731
SP  - 327
EP  - 339
ER  - 
TY  - JOUR
A1  - Scherer, Ulrich W.
A1  - Gäggeler, H. W.
A1  - Jost, D. T.
A1  - Kovacs, J.
T1  - Gas Phase Chromatography Experiments with Bromides of Tantalum and Element 105 / H.W. Gäggeler, D.T. Jost, J. Kovacs, U.W. Scherer, A. Weber, D. Vermeulen, A. Türler, K.E. Gregorich, R.A. Henderson, K.R. Czerwinski, B. Kadkhodayan, D.M. Lee, M. Nurmia, D.
JF  - Radiochimica Acta. 57 (1992)
Y1  - 1992
SN  - 0033-8230
SP  - 93
EP  - 100
ER  - 
TY  - JOUR
A1  - Mang, Thomas
A1  - Roosen, Christoph
A1  - Ansorge-Schumacher, Marion
A1  - Leitner, Walter
T1  - Gaining pH-control in water/carbon dioxide biphasic systems / Roosen, Christoph ; Ansorge-Schumacher, Marion ; Mang, Thomas ; Leitner, Walter ; Greiner, Lasse
JF  - Green Chemistry. 9 (2007)
Y1  - 2007
SN  - 1463-9262
SP  - 455
EP  - 458
ER  - 
TY  - JOUR
A1  - Mang, Thomas
A1  - Roosen, C.
A1  - Ansorge, M.
A1  - Leitner, W.
T1  - Gaining pH-control in water/carbon dioxide biphasic systems / Abstract No. 1038 / Roosen, Ch. ; Ansorge, M. ; Mang, Thomas ; Leitner, W. ; Greiner, L.
JF  - Green solvents for processes : Lake Constance, Friedrichshafen, Germany, 8 - 11 October 2006 ; book of abstracts / DECHEMA e.V.
Y1  - 2006
N1  - DECHEMA, Gesellschaft für Chemische Technik und Biotechnologie ; [Conference] ; ((Friedrichshafen) : 2006.10.08-11)
PB  - DECHEMA
CY  - Frankfurt am Main
ER  -